CEO Kelly Jared buys 5,050 shares of ONCY at $0.96; third purchase in 30 days as stock recovers +14.8% in 30 days from near-lows.
Kelly Jared, ONCY's CEO, purchased 5,050 shares at $0.96 on 2026-03-12, marking his third consecutive buy in roughly a month (prior buys on 2026-02-12 and 2026-02-11). The stock is currently trading at $0.98, up 14.8% over the 30-day period, though still down 31.0% from its 52-week high of $1.42 and well above the 52-week low of $0.33. His holdings now stand at 114,050 shares post-transaction. The repeated buying pattern at depressed valuations in a micro-cap ($78.4M market cap) warrants attention, but measurable outcomes for these recent purchases remain limited—his prior trade at this ticker on 2026-02-11 shows a 30-day return of +17.7%, though the 90-day horizon is not yet assessable. Investors should monitor whether this accumulation reflects founder confidence or merely discretionary capital deployment in a volatile micro-cap.
CEO Kelly Jared purchases 35,100 shares at $0.84 in 2 transactions; 8 other insiders also bought within 14 days
Kelly Jared, CEO of Oncolytics Biotech, executed 2 separate purchases totaling 35,100 shares for $29,520.60, expanding his holdings by 47.5% from 73,900 to 109,000 shares. The transaction price of $0.84 per share is positioned 20.8% below the current price of $1.06 and near the 52-week low of $0.33, suggesting accumulation during a depressed period in the stock's recent range. The cluster pattern—8 other insiders also buying within the past 14 days—indicates coordinated insider confidence rather than isolated trading activity. This multi-insider buying at uniformly low prices warrants investor attention to the underlying fundamentals and near-term catalysts that may have triggered the synchronized accumulation.
